Chalazion

Evidence-based assessment and management of meibomian gland lipogranuloma. Comprehensive guide covering etiology, pathogenesis, classification, diagnosis, and treatment protocols for optometry practice.

Last updated: March 2026

Left: External presentation of a chalazion as a firm, non-tender nodule in the upper eyelid. Right: Sagittal cross-section showing meibomian gland obstruction with inspissated meibum plug, lipogranulomatous inflammation with epithelioid and multinucleated giant cells, fibrotic capsule, and conjunctival elevation visible on lid eversion.

A chalazion (plural: chalazia; from Greek khalazion, meaning small hailstone) is a chronic, sterile lipogranulomatous inflammatory lesion arising from obstruction of a meibomian gland (tarsal gland) duct, with subsequent retention and periductal leakage of lipid-rich meibomian secretions into the surrounding lid stroma. The extravasated lipid provokes a foreign-body granulomatous response, producing the characteristic firm, encapsulated nodule within the tarsal plate.

Chalazia are among the most common eyelid lesions encountered in optometry and ophthalmology practice. They affect all age groups but are most prevalent in adults between the third and fifth decades of life. The upper eyelid — which contains 30–40 meibomian glands compared to 20–30 in the lower — is more frequently affected. The condition is strongly associated with chronic posterior blepharitis, meibomian gland dysfunction (MGD), and sebaceous skin disorders such as rosacea and seborrhoeic dermatitis.

The vast majority of chalazia resolve with conservative management or minor outpatient procedures. However, a small but clinically important subset of recurrent or atypical lesions may represent sebaceous gland carcinoma — a potentially life-threatening malignancy — making biopsy of histologically suspicious cases essential.

Primary Cause: Meibomian Gland Duct Obstruction

The proximate cause in virtually all cases is obstruction of the meibomian gland ductal orifice, leading to inspissation and retention of meibomian secretions. The underlying drivers include:

Hyperkeratinisation of the ductal epithelium: Excessive keratin production within the meibomian duct narrows or occludes the lumen; associated with seborrhoeic and rosacea phenotypes
Abnormal meibum viscosity: High melting-point meibum (associated with omega-3 deficiency, rosacea, and ageing) solidifies within the duct and impedes flow
Chronic posterior blepharitis: Inflammatory mediators directly damage meibomian gland architecture and alter secretion composition
Meibomian gland dysfunction (MGD): The single most important predisposing condition; encompasses all forms of meibomian secretory and ductal pathology

Associated Conditions

Ocular rosacea: Meibomian gland and conjunctival involvement occurs in up to 58% of cutaneous rosacea patients; chalazia are a hallmark complication
Seborrhoeic dermatitis: Scalp and facial seborrhoea with oily skin promotes meibomian hypersecretion and ductal plugging
Acne vulgaris: Shared pathophysiology of sebaceous gland hyperactivity and ductal obstruction
Demodex folliculorum and D. brevis infestation: Demodex mites colonise meibomian glands and lash follicles; their presence is associated with increased gland inflammation, ductal hyperkeratosis, and chalazion recurrence. D. brevis has a predilection for the meibomian gland body itself.
Previous chalazion: Scarring of the gland duct predisposes to recurrence at or adjacent to the same site
Hormonal factors: Androgens regulate meibomian gland secretion; pubertal, pregnancy-related, and perimenopausal hormonal shifts alter meibum production and quality
Immunosuppression: HIV infection, organ transplantation, and long-term immunosuppressive therapy predispose to atypical and recurrent chalazia
Diabetes mellitus: Altered sebaceous secretion and impaired immune clearance contribute to recurrent lid infections and inflammatory lesions
Contact lens wear: Chronic lid margin mechanical irritation and altered lid environment promote meibomian gland dysfunction

Stepwise Pathological Sequence

Ductal obstruction: Hyperkeratosis of the meibomian gland ductal epithelium or inspissation of high-viscosity meibum occludes the ductal orifice at the posterior lid margin.
Secretion retention and gland distension: Continued secretory activity distends the gland acini with retained lipid-rich meibum, elevating intraglandular pressure.
Gland rupture and lipid extravasation: Under sustained pressure, the gland wall ruptures, releasing wax esters, cholesteryl esters, and triglycerides — the major lipid constituents of meibum — into the surrounding tarsal connective tissue and lid stroma.
Foreign-body granulomatous reaction: Extravasated lipids are recognised as foreign material by resident macrophages. Lipid-laden (foamy) macrophages, epithelioid histiocytes, and multinucleated Langhans-type giant cells accumulate, forming a granuloma that attempts to contain and digest the lipid.
Lymphocytic infiltrate: T-lymphocytes and plasma cells contribute to the chronic inflammatory infiltrate surrounding the lipid-laden macrophages. This explains the non-infectious, immune-mediated nature of the lesion.
Fibrous encapsulation: Progressive fibrous tissue deposition around the granuloma produces the characteristic firm, encapsulated nodule palpable within the tarsal plate.
Eventual resolution or fibrocalcific change: Smaller chalazia may resorb completely. Larger lesions may undergo dystrophic calcification or form a permanent fibrous scar within the tarsus.

Histopathology

Lipid vacuoles (cleared on standard formalin fixation, appearing as empty spaces) within a granulomatous infiltrate
Foamy (lipid-laden) macrophages and multinucleated giant cells
Surrounding lymphocytes, plasma cells, and eosinophils
Fibrous capsule of variable thickness
Critical distinction: Unlike sebaceous gland carcinoma, chalazion shows no cellular atypia, no atypical mitoses, and no pagetoid intraepithelial spread. Histopathological examination is mandatory for recurrent, atypical, or suspicious lesions.

Distinction from Internal Hordeolum

An internal hordeolum is an acute suppurative (bacterial) infection of the meibomian gland, most commonly caused by Staphylococcus aureus. Chalazion, in contrast, is a chronic sterile inflammatory lipogranuloma. Clinically, a hordeolum presents acutely with pain, erythema, and tenderness; it may evolve into a chalazion if the acute infection resolves but leaves a residual blockage and retained lipid with ongoing granulomatous reaction.

By Gland of Origin

Meibomian gland chalazion (most common): Arises from a tarsal gland; located deeper within the tarsal plate; presents as a nodule palpable through the lid skin and visible on the tarsal conjunctival surface on eversion
Zeis gland chalazion: Arises from the sebaceous glands of Zeis associated with lash follicles; located more anteriorly, near the lid margin; less common

By Anatomical Location

Upper eyelid: More common (30–40 meibomian glands); lesions here are more likely to cause mechanical ptosis and corneal astigmatism due to tarsal plate size
Lower eyelid: Less common (20–30 meibomian glands)
Marginal chalazion: Near the lid margin; may be confused with hordeolum or lid margin tumour

By Clinical Stage

Stage	Clinical Features	Tenderness	Management
Acute (Early)	Warm, tender, erythematous lid swelling; overlaps clinically with internal hordeolum	Yes — painful	Warm compresses; topical antibiotic if infection suspected
Subacute	Tenderness resolving; firm nodule forming within tarsus; redness subsiding	Mild or absent	Warm compresses; observe; consider steroid injection
Chronic (Classic)	Firm, non-tender, well-circumscribed, mobile lid nodule; no overlying erythema; tarsal conjunctival elevation on eversion	None	Intralesional steroid or incision and curettage (I&C)
Pointing / Discharging	Spontaneous pointing through skin or conjunctiva; lipogranulomatous material extrudes; pyogenic granuloma may develop on conjunctival surface	Variable	I&C plus granuloma excision if present

By Number and Distribution

Solitary: Single lesion; most common presentation
Multiple (concurrent): Suggest significant underlying MGD, rosacea, seborrhoeic dermatitis, or Demodex infestation
Recurrent (same site): High suspicion for sebaceous gland carcinoma — biopsy mandatory
Bilateral: More likely in systemic association (rosacea, immunosuppression)

Ocular and Lid-related

Chronic posterior blepharitis — the most prevalent and directly causative risk factor
Meibomian gland dysfunction (obstructive and hyposecretory subtypes)
Previous chalazion at the same or adjacent site
Demodex infestation (cylindrical collarettes at lash bases)
Contact lens wear (altered lid flora, increased mechanical lid irritation)
History of stye (internal hordeolum) with incomplete resolution

Systemic and Dermatological

Ocular and cutaneous rosacea (erythema, telangiectasia, rhinophyma)
Seborrhoeic dermatitis (dandruff, oily scalp and facial skin)
Acne vulgaris (sebaceous gland hyperactivity)
Diabetes mellitus (impaired immune response and wound healing)
Immunosuppressive states: HIV/AIDS, organ transplant recipients, long-term corticosteroid use
Hypercholesterolaemia (altered lipid composition of meibum)

Demographic and Lifestyle

Young to middle-aged adults most commonly affected; less common in children and the elderly (though sebaceous carcinoma risk rises steeply after age 60)
No consistent sex predilection, though hormonal influences (androgens) modulate meibomian secretion
Oily skin phenotype (high sebaceous gland activity)
Poor lid hygiene
Diet low in omega-3 fatty acids (affects meibum quality)
High screen time with reduced blink rate (promotes meibum stasis and gland dysfunction)

Eyelid Signs

Firm, non-tender, well-circumscribed nodule: The hallmark of chronic chalazion; freely mobile within the tarsus; overlying skin not adherent (unlike dermoid cysts)
Painless lid swelling causing localised lid thickening or visible mound; size ranges from 1–2 mm to 1–2 cm
Acute phase: Erythema, warmth, and tenderness of the involved lid segment; overlaps clinically with internal hordeolum
Mechanical ptosis: Large upper lid chalazia press against the levator aponeurosis, causing ptosis proportional to size
Skin pointing: Thinning and reddening of overlying lid skin as a large chalazion approaches the surface (external drainage pathway)

Tarsal Conjunctival Signs (on Lid Eversion)

Localised reddish-grey or yellowish elevation on the tarsal conjunctival surface, corresponding precisely to the lid nodule
Central pale or yellow zone reflecting lipid content
Surrounding conjunctival hyperaemia and inflammation
Pyogenic granuloma: a vascular, friable, pedunculated red mass on the tarsal conjunctiva — indicates spontaneous rupture with chronic mucosal irritation

Associated Lid Margin and Meibomian Gland Signs

Inspissated meibomian gland orifices (toothpaste-like secretion on expression)
Lid margin telangiectasia and irregular thickening (MGD/rosacea)
Collarette deposits at lash bases (Demodex)
Crusting, scaling, or erythema of lid margin (blepharitis)
Poliosis (lash whitening) in longstanding or recurrent lesions overlying an individual gland

Ocular Surface and Corneal Signs

Corneal astigmatism: Mechanical pressure from a large chalazion on the cornea induces with-the-rule or irregular astigmatism; may be significant (>1D) in children
Tear film instability from concurrent MGD: reduced TBUT, irregular lipid layer on interferometry
Punctate epithelial erosions from tear film dysfunction
Superior corneal pannus or conjunctival scarring in longstanding cases with chronic ocular surface irritation

Painless lid lump: The predominant presenting complaint in chronic chalazion; noticed by the patient as a firm swelling in the lid
Tenderness and pain (acute phase): Significant discomfort at onset when the inflammatory phase is active; diminishes as the lesion matures into a chronic granuloma
Sensation of heaviness or pressure in the eyelid: From the mass effect of the nodule within the tarsus, particularly with larger lesions
Blurred or fluctuating vision: Caused by mechanically induced corneal astigmatism from lid compression; more pronounced with large upper lid lesions and clinically significant in children
Cosmetic concern: Visible lid deformity causes psychological distress, particularly in young adults and children
Mild foreign body sensation or eye irritation: From conjunctival surface involvement when the tarsal conjunctiva is affected
Tearing (epiphora): From conjunctival irritation or impaired lacrimal drainage if the lesion lies near the punctum
Recurrent symptoms at the same site: Strongly associated with underlying MGD, rosacea, or — rarely — sebaceous carcinoma

Note: The transition from a painful acute lid swelling to a painless chronic nodule over days to weeks is characteristic of the chalazion lifecycle. Persistence beyond 4–6 weeks without improvement, or recurrence after drainage, should prompt reassessment and consideration of excision biopsy to exclude malignancy.

Visual Complications

Induced corneal astigmatism: Mechanical pressure from a large chalazion compresses the cornea, inducing irregular or with-the-rule astigmatism; significant in children (>1D may cause anisometropic amblyopia)
Amblyopia (in children): Prolonged astigmatism or visual axis occlusion by a large chalazion during the critical visual development period (birth to age 7–8 years) is a recognised and preventable cause of amblyopia; urgent management is warranted in paediatric patients
Mechanical ptosis: Upper lid chalazia may cause significant ptosis, further reducing visual input and contributing to amblyopia risk in children

Local Complications

Secondary bacterial infection: Conversion of a chalazion to an acute internal hordeolum with pain, fluctuance, and purulent discharge; requires topical or systemic antibiotics
Spontaneous external pointing and discharge: Lipogranulomatous contents drain through the thinned overlying skin; may leave a residual scar or skin indentation
Spontaneous conjunctival drainage: Pointing through the tarsal conjunctiva with chronic irritation of the ocular surface and conjunctival scarring
Pyogenic granuloma: Vascular, friable, rapidly growing red conjunctival or skin mass arising at the site of drainage or after incision and curettage; requires surgical excision
Fistula formation: Chronic drainage tract through skin or tarsal conjunctiva persisting after incomplete resolution
Tarsal scarring and contour deformity: Repeated incision, recurrence, or spontaneous drainage scars the tarsal plate, distorting lid architecture
Preseptal cellulitis: Spread of secondary bacterial infection to periorbital soft tissues; presents with diffuse lid erythema, oedema, and tenderness; requires systemic antibiotics

Missed Diagnosis

Sebaceous gland carcinoma masquerade: The most important complication of delayed or missed diagnosis. Sebaceous carcinoma frequently presents as a recurrent, unilateral "chalazion," particularly in the upper lid of an older patient. Pagetoid spread to the conjunctiva and skin may be clinically invisible until advanced. A missed diagnosis can result in orbital exenteration or death. All recurrent chalazia in the same site must be biopsied.

Treatment-related Complications

Intralesional corticosteroid injection:
- Skin or conjunctival depigmentation (particularly in darkly pigmented patients; use trans-conjunctival approach to reduce risk)
- Subcutaneous fat atrophy and lid contour irregularity
- Intraocular pressure elevation (transient; monitor)
- Rare: inadvertent globe perforation; intravascular injection
Incision and curettage (I&C):
- Bleeding; haematoma
- Tarsal plate notching or lid contour deformity from over-aggressive curettage
- Conjunctival scarring and symblepharon (rare)
- Incomplete clearance with recurrence
- Corneal abrasion from the lid plate clamp

Key Systemic Associations

Rosacea (most important systemic association): A chronic inflammatory skin condition affecting the centrofacial region, characterised by flushing, persistent erythema, telangiectasia, and papulopustular lesions. Ocular rosacea occurs in up to 58% of patients with cutaneous rosacea and frequently precedes skin manifestations. Rosacea-associated MGD directly predisposes to chalazion formation. Examine for facial erythema, telangiectasia across nose and cheeks, rhinophyma, and papulopustular lesions. Refer to dermatology for systemic treatment (oral doxycycline, azelaic acid, topical metronidazole).
Seborrhoeic dermatitis: Chronic sebaceous gland over-activity causing dandruff (scalp), oily facial skin, retroauricular scaling, and nasolabial fold involvement. Co-existing anterior blepharitis (scurf, collarettes) promotes posterior meibomian gland disease and chalazion.
Acne vulgaris: Shared pathophysiology of pilosebaceous ductal obstruction, sebaceous hyperactivity, and propionibacterial colonisation; chalazion formation reflects the equivalent process in meibomian glands.
Diabetes mellitus: Hyperglycaemia impairs neutrophil function and wound healing; associated with recurrent lid infections, non-healing post-procedural wounds, and multiple or bilateral chalazia. Recurrent chalazia may be the first clinical indicator prompting blood glucose screening.
HIV/AIDS and immunosuppression: Atypical, multiple, and recurrent chalazia are a recognised manifestation of HIV-related ocular disease. Multiple concurrent chalazia in a young patient should prompt consideration of immunosuppressive states.
Crohn's disease: Granulomatous inflammation of the gastrointestinal tract may have extraintestinal manifestations including granulomatous lid infiltration presenting as chalazion-like lesions.
Sarcoidosis: Systemic granulomatous disease; lacrimal gland and eyelid infiltration may produce eyelid nodules histologically resembling but clinically distinct from chalazia. Associated anterior uveitis, optic neuropathy, and pulmonary involvement.

Sebaceous Gland Carcinoma — The Critical Masquerade

High-risk features warranting biopsy: Recurrent chalazion at the same site; unilateral recurrent chalazion; upper lid predominance in an elderly patient; yellow, waxy, or irregular nodule; loss of lashes (madarosis) at the affected lid; diffuse lid thickening (masquerade syndrome); unilateral chronic conjunctivitis or blepharitis refractory to treatment; pagetoid spread to adjacent conjunctiva. Sebaceous gland carcinoma has a 5-year mortality of 14–38% if not diagnosed and treated early.

Systemic Workup Indications

Recurrent or multiple bilateral chalazia: screen for rosacea, diabetes (fasting glucose / HbA1c), and immunosuppression
Young patient with multiple chalazia: consider HIV testing if other risk factors present
Associated facial erythema, telangiectasia: refer to dermatology for rosacea evaluation
Associated anterior uveitis or lung symptoms: consider sarcoidosis workup (chest X-ray, ACE level, serum calcium)
Recurrent chalazion in elderly — excision biopsy histopathology to exclude sebaceous carcinoma

Clinical History

Duration of lid swelling and rate of change (rapid growth is atypical)
Number of previous episodes and whether they recurred at the same site
Onset character: acute painful (hordeolum evolution) vs. insidious (primary chalazion)
Prior treatments and response (warm compresses, antibiotics, steroid injection, surgery)
Systemic conditions: rosacea, seborrhoeic dermatitis, diabetes, immunosuppression
Medications: topical eye drops (prostaglandin analogues alter periorbital skin pigmentation), systemic immunosuppressants
Family history: sebaceous carcinoma or other eyelid tumours
Contact lens use; screen time and blink habits

Clinical Examination

1. External Lid Examination:

Palpate lid nodule: size (mm), location (upper/lower, medial/central/lateral), mobility, tenderness, fixation to skin or tarsus
Assess overlying skin: erythema, thinning, fistulous openings, skin fixation (adhesion raises malignancy concern)
Measure palpebral aperture and check for mechanical ptosis
Assess lash integrity: madarosis (lash loss) is a red flag for malignancy
Examine all four lids for additional lesions (multiple lesions suggest systemic cause)

2. Lid Eversion:

Essential for all lid lesions: examine the tarsal conjunctival surface of both upper and lower lids
Chalazion: reddish-grey or yellowish tarsal conjunctival elevation corresponding to the palpable nodule
Pyogenic granuloma: vascular, pedunculated mass at drainage site
Assess for diffuse tarsal conjunctival thickening or loss of normal gland architecture (sebaceous carcinoma masquerade)

3. Slit Lamp Biomicroscopy:

Lid margin: Document meibomian gland orifice obstruction, telangiectasia, irregularity, collarettes (Demodex)
Meibomian gland expression: Assess secretion quality (clear fluid to toothpaste-like; grading by Mathers or Korb-Blackie scale)
Cornea: Assess for induced astigmatism (irregular mires on keratometry), punctate epithelial erosions, corneal staining with fluorescein
Tear film: TBUT; tear meniscus height; assess lipid layer quality
Conjunctiva: Injection, papillary reaction, focal thickening, or abnormal vascularity

4. Supplementary Tests and Imaging:

Meibography (infrared):

Identifies meibomian gland dropout, truncation, and distortion — quantifies underlying MGD severity contributing to chalazion formation
Useful for guiding long-term MGD management and documenting baseline gland loss before treatment

Corneal Topography / Keratometry:

Quantifies chalazion-induced corneal astigmatism; mandatory in paediatric patients to assess amblyopia risk
Post-treatment topography confirms corneal recovery and guides refractive correction

Excision Biopsy with Histopathology (mandatory indications):

Recurrent chalazion at the same site — highest priority indication
Atypical morphology: loss of lashes, skin fixation, diffuse lid thickening, yellow waxy texture
Elderly patient (≥60 years) with first occurrence of unilateral upper lid chalazion
Failed response to standard treatments without clear explanation
Rapid or unusual growth rate

Ocular Ultrasound (B-scan):

Rarely needed; considered if lesion is deep, fixed, or there is concern for orbital extension of an underlying malignancy

Singapore Optometry Scope Note: Optometrists may initiate and direct conservative management including warm compresses, lid hygiene, Demodex treatment, and MGD therapy. Slit lamp assessment, meibography, corneal topography, and fluorescein staining are within scope. Prescription of topical antibiotics (if secondary infection is present) requires referral to a medical practitioner or ophthalmologist. Intralesional steroid injection and incision and curettage (I&C) are surgical procedures requiring ophthalmology referral. As optometrists in Singapore do not perform dilated fundus examination, if posterior segment evaluation is warranted (e.g., to exclude orbital or posterior segment involvement in atypical or malignant-appearing lesions), refer to an ophthalmologist. Recurrent chalazia at the same site must be referred for excision biopsy to exclude sebaceous gland carcinoma.

1. Conservative Management (First-line for All Stages)

Warm compresses: 10 minutes, 4 times daily; heat softens inspissated meibum, dilates ductal orifices, and improves meibomian gland flow. A purpose-designed heated eyemask (Bruder® or equivalent) maintains a consistent temperature of ~45°C more effectively than a wet flannel. Effective in up to 50% of acute and small chalazia within 2–4 weeks.
Lid massage: Following warm compresses, firm outward massage (upper lid downward, lower lid upward) expresses softened secretions and promotes gland drainage
Lid hygiene: Twice-daily lid scrubs with commercial lid wipes (e.g., Blephaclean, Blephasol) or diluted baby shampoo; removes lid margin debris, biofilm, and Demodex products promoting ductal obstruction
Demodex-targeted treatment (if collarettes present): Tea tree oil (TTO)-based lid cleanser (e.g., Cliradex, I-Lid 'n Lash Plus); 4-Terpineol is the active antiparasitic component. Apply daily for 6–8 weeks. Oral ivermectin (200 mcg/kg single dose, repeated at 1 week) may be used in severe infestation (requires medical prescription).
Topical antibiotics (if secondary infection): Chloramphenicol 0.5% drops or ointment, or fusidic acid 1% gel for 5–7 days; requires prescription
Oral doxycycline (for rosacea-associated or refractory MGD): 50–100 mg once daily for 3–6 months; anti-inflammatory properties reduce meibomian gland inflammation and alter meibum composition independently of antibiotic effects. Requires medical prescription.
Omega-3 fatty acid supplementation: Fish oil 2–3 g daily; improves meibum lipid composition and reduces evaporative dry eye; adjunctive in MGD-driven chalazion recurrence

2. Intralesional Corticosteroid Injection (Intermediate Treatment)

Indicated when conservative management over 3–4 weeks fails to produce resolution, or as primary treatment for larger lesions (>5 mm) or multiple chalazia.

Agent: Triamcinolone acetonide 10–40 mg/mL; 0.05–0.2 mL injected directly into the chalazion
Approach: Trans-conjunctival (through everted lid tarsal conjunctiva) preferred over transcutaneous — lower risk of skin depigmentation, particularly in patients with darker skin tones
Efficacy: Complete or near-complete resolution in 70–80% of cases; may require a second injection after 3–4 weeks if partial response
Advantages: Avoids surgical incision; suitable for multiple lesions; can be performed in an outpatient setting
Key risks: Skin depigmentation (use trans-conjunctival approach); subcutaneous fat atrophy; transient IOP elevation (monitor in glaucoma patients); rare globe perforation with inexperienced technique

3. Incision and Curettage (I&C) — Definitive Surgical Treatment

First-line surgical option for large, chronic, non-resolving chalazia or those that have failed conservative treatment and intralesional injection. Success rate exceeds 90%.

Procedure: Under local anaesthesia (lidocaine 2% with adrenaline injected into the lid), a Desmarres or similar lid clamp is applied. A vertical incision (1–2 mm) is made through the tarsal conjunctiva perpendicular to the lid margin to avoid cutting across meibomian gland ducts. The granulomatous contents are curetted and the fibrous capsule wall scored.
Histopathology: All excised material from recurrent, atypical, or elderly-patient chalazia must be sent for histopathological examination
Post-operative care: Topical antibiotic ointment (chloramphenicol) 4 times daily for 5–7 days; pressure pad for 30–60 minutes; warm compresses resume after 48 hours
Pyogenic granuloma: Excise at the time of I&C; apply silver nitrate chemical cautery to the base if needed

4. Long-term Management of Underlying MGD and Rosacea

Treating the chalazion without addressing its underlying cause results in high recurrence rates. The following should be implemented concurrently and maintained long-term:

Sustained lid hygiene programme (twice daily, indefinitely for MGD/rosacea patients)
Heated eyemask therapy (nightly or twice daily)
In-office meibomian gland expression at clinic visits
Intense Pulsed Light (IPL) therapy: targets telangiectatic vessels in rosacea; reduces lid margin inflammation and normalises meibum; emerging evidence supports use in recurrent chalazion associated with rosacea and MGD
Dermatology co-management for rosacea: oral doxycycline, azelaic acid, topical metronidazole, or laser treatments

Treatment Selection Guide

Scenario	First-line	If No Response	Referral
Acute chalazion / small (<5 mm)	Warm compresses + lid hygiene 4–6 weeks	Intralesional steroid injection	Ophthalmology if injection needed or no resolution
Large chalazion (≥5 mm) or chronic	Intralesional steroid injection or I&C	I&C if injection fails; repeat I&C if recurrence	Ophthalmology — I&C is a surgical procedure
Multiple chalazia / both lids	Treat underlying MGD/rosacea; warm compresses; oral doxycycline	Sequential injection or I&C for persistent lesions	Ophthalmology + dermatology co-management
Chalazion in a child	Warm compresses; lid hygiene; check for induced astigmatism	I&C under general anaesthesia if no resolution; urgent if amblyopia risk	Urgent ophthalmology if visual acuity affected or amblyopia risk
Recurrent chalazion / atypical features	Excision biopsy with histopathology to exclude sebaceous carcinoma	Oncology / oculoplastics management based on histology	Urgent ophthalmology referral

Resolution Rates

Spontaneous resolution: Up to 25–50% of small chalazia (<5 mm) resolve spontaneously within 2–6 months without intervention. Warm compresses significantly increase this rate.
Conservative management (warm compresses + lid hygiene): Effective in approximately 50% of cases within 4–6 weeks for small to medium lesions
Intralesional corticosteroid injection: Complete or near-complete resolution in 70–80% of cases; second injection may be required after 4 weeks if partial response
Incision and curettage (I&C): The most effective intervention; success rate exceeds 90%; recurrence at the same site after adequate I&C is uncommon and should prompt histopathological examination

Recurrence and Long-term Outlook

Recurrence at the same site following adequate treatment should trigger biopsy to exclude sebaceous gland carcinoma
Recurrence at a new site on the same or fellow lid reflects inadequately treated underlying MGD, rosacea, or Demodex infestation — not true recurrence of the treated lesion
With effective long-term treatment of the underlying MGD and sebaceous gland disease (lid hygiene, doxycycline, IPL therapy), recurrence rates are substantially reduced
Paediatric patients: Prognosis for visual recovery is excellent if chalazion-induced astigmatism and amblyopia are identified and managed early; regular refractive monitoring is essential after treatment
Corneal astigmatism recovery: Induced astigmatism typically resolves within weeks of chalazion treatment; refractive reassessment should be performed 4–6 weeks post-treatment before prescribing spectacles
Visual prognosis in malignancy (sebaceous carcinoma): Outcome depends critically on early detection and adequate surgical clearance; pagetoid spread or orbital involvement carries a significantly worse prognosis

Condition	Key Distinguishing Features	Tenderness	Action
Chalazion	Firm, non-tender, well-circumscribed tarsal nodule; sterile; reddish-grey tarsal conjunctival elevation on eversion	None (chronic)	Conservative; injection; I&C
Internal Hordeolum (Stye)	Acute, painful, erythematous meibomian gland abscess; suppurative (bacterial); points toward conjunctiva; rapid onset over 1–2 days	Marked	Warm compresses; topical antibiotics; I&D if fluctuant
External Hordeolum (Stye)	Infection of Zeis or Moll gland at lid margin; acute; small pustule at lash base; points externally	Marked	Warm compresses; lid hygiene; topical antibiotics
Sebaceous Gland Carcinoma	Recurrent "chalazion" at same site; upper lid > lower; madarosis; yellow/waxy nodule; diffuse lid thickening; pagetoid conjunctival spread; elderly patient; fixed, indurated	Variable	Urgent excision biopsy; oncology referral
Basal Cell Carcinoma (BCC)	Pearly, rolled-edge nodule; lid margin; loss of lashes; central ulceration (rodent ulcer); lower lid > upper; elderly	None	Excision biopsy; Mohs surgery
Squamous Cell Carcinoma (SCC)	Hyperkeratotic, crusted, irregular lid lesion; irregular telangiectasia; may ulcerate; sun-exposed skin; actinic keratosis background	Variable	Excision biopsy; Mohs surgery
Pyogenic Granuloma	Rapidly growing, vascular, friable, pedunculated red mass; history of prior chalazion drainage, trauma, or I&C; bleeds easily on contact	Mild	Surgical excision; silver nitrate cautery
Epidermoid Inclusion Cyst (EIC)	Smooth, white-yellowish, superficial cyst near lash base or skin; freely mobile; contains keratin not lipid; no tarsal involvement on eversion	None	Observe; excision if cosmetically problematic
Milia	Multiple tiny (1–2 mm) white keratin cysts; very superficial; no tarsal involvement; often bilateral; common in fair-skinned individuals	None	Needle extraction; laser ablation
Preseptal (Periorbital) Cellulitis	Diffuse lid erythema, warmth, tenderness, and swelling; systemic signs (fever); no discrete nodule; history of trauma, insect bite, or upper respiratory infection	Marked	Urgent systemic antibiotics; ophthalmology if orbital involvement suspected

Critical Clinical Rule: Any chalazion that recurs at the same site after adequate treatment — regardless of the patient's age or apparent benign morphology — must be excised and submitted for histopathological examination to exclude sebaceous gland carcinoma. This principle is non-negotiable and constitutes the minimum standard of care for recurrent lid nodules.

Nemet AY, Vinker S, Kaiserman I. Associated morbidity of chalazia. Cornea. 2011;30(12):1376–1381.
Ben Simon GJ, Rosen N, Rosner M, Spierer A. Intralesional triamcinolone acetonide injection versus incision and curettage for primary chalazia: a prospective, randomized study. Am J Ophthalmol. 2011;151(4):714–718.
Ozdal PC, Codère F, Callejo S, Caissie AL, Burnier MN. Accuracy of the clinical diagnosis of chalazion. Eye (Lond). 2004;18(2):135–138.
Goawalla A, Lee V. A prospective randomized treatment study comparing three treatment options for chalazia: triamcinolone acetonide injections, incision and curettage and treatment with hot compresses. Clin Experiment Ophthalmol. 2007;35(8):706–712.
Chun YS, Park IK. Sebaceous carcinoma of the eyelids: 30-year experience at a single institution in an Asian population. Jpn J Ophthalmol. 2015;59(4):257–261.
Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):3089–3094.
Bernardes TF, Bonfioli AA. Blepharitis. Semin Ophthalmol. 2010;25(3):79–83.
Wladis EJ. Management of chalazion. Curr Opin Ophthalmol. 2023;34(5):403–408.
Ho M, Ho WL, Lee A, Lai JSM. Intralesional steroid injection for the treatment of chalazions: a systematic review. J Ophthalmol. 2017;2017:3718102.
Gilchrist H, Lee G. Management of chalazia in general practice. Aust Fam Physician. 2009;38(5):311–314.
Pizzarello LD, Jakobiec FA, Folberg R, Iwamoto T, Knowles DM. Intralesional corticosteroid therapy of chalazia. Am J Ophthalmol. 1978;85(6):818–821.
Scheuerle AF, Steiner HH, Kolling G, Kunze S, Aschoff A. Treatment and long-term outcome of patients with orbital cavernomas. Am J Ophthalmol. 2004;138(2):237–244.
Khorshidifar M, Sadeghi-Tari A, Ghavami-Shahri SH. Correlation of meibomian gland dysfunction and chalazion formation in patients with anterior and posterior blepharitis. J Ophthalmic Vis Res. 2020;15(2):147–153.
Dhingra D, Bhatt H. Update on chalazion management. Curr Opin Ophthalmol. 2019;30(5):332–338.
Yam JC, Tang BS, Chan TM, Cheng AC. Ocular demodicidosis as a risk factor of adult recurrent chalazion. Eur J Ophthalmol. 2014;24(2):159–163.

Clinical Illustration

Overview

Etiology